Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Presumed to be non-addictive with low abuse potential, similar to LSD. Animal studies with LSD show no self-administration behavior, indicating it lacks the pharmacology to initiate or maintain dependence.
Virtually no withdrawal syndrome is reported when chronic use of LSD or its analogs is stopped, suggesting 1cP-LSD carries minimal physical dependence potential.
No known toxic dose has been established. The toxicity and long-term health effects of recreational use have not been formally studied due to its status as a novel research chemical with limited history of human use.
May act as a trigger for psychotic episodes in individuals with underlying mental disorders or family history of mental illness. Higher doses increase the risk of adverse psychological reactions including anxiety, delusions, and panic attacks. Those with a personal or family history of mental illness are generally advised not to use this substance.
Seizure risk is largely extrapolated from LSD reports and is primarily a concern for those genetically predisposed, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.
1cP-LSD was developed by Lizard Labs, a research chemical laboratory based in the Netherlands, as a legal alternative to LSD. The compound emerged on the grey market around 2019, reportedly created in anticipation of the impending prohibition of 1P-LSD in Germany. Like its predecessor, 1cP-LSD is…
Not listed as a controlled substance under Canadian drug control legislation. Remains legal to possess and purchase.
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 2, 2021. Production and importation with intent to distribute, administration to others, and commercial trading are criminal offenses. Possession is prohibited but carries no penalty. Prior to this date, 1cP-LSD existed in a legal grey area as its cyclopropylcarbonyl group was not considered an alkyl radical under the original NpSG amendment regulation.
Sweden's public health agency proposed classification as a dangerous substance on December 18, 2019. Formally classified as such on April 22, 2021.
Covered by the Psychoactive Substances Act 2016, effective May 26, 2016. Production, supply, and importation are criminal offenses. Personal possession is not penalized under this legislation, though the substance cannot be legally sold for human consumption.
Not designated as a controlled substance and does not appear on the national list of prohibited drugs.
Regulated under the Pharmaceutical Affairs Law. Both possession and sale are prohibited.
Classified as a controlled drug. Possession, production, supply, and importation are all criminal offenses.
16 sources cited
